Truist Financial analyst Joon Lee assigned a Buy rating to Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of $83.99. The company’s shares closed yesterday at $86.06.
According to TipRanks, Lee is a 5-star analyst with an average return of 24.6% and a 55.88% success rate. Lee covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Corcept Therapeutics, and Axsome Therapeutics.
In addition to Truist Financial, Crispr Therapeutics AG also received a Buy from Chardan Capital’s Geulah Livshits in a report issued on February 21. However, yesterday, Morgan Stanley maintained a Sell rating on Crispr Therapeutics AG (NASDAQ: CRSP).
See today’s best-performing stocks on TipRanks >>
Based on Crispr Therapeutics AG’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $201.21 million and a net profit of $89.35 million. In comparison, last year the company earned a revenue of $768 thousand and had a GAAP net loss of $110.58 million
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CRSP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Crispr Therapeutics AG (CRSP) Company Description:
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
Read More on CRSP:
- Crispr Therapeutics call volume above normal and directionally bullish
- Crispr Therapeutics price target raised to $66 from $57 at RBC Capital
- Crispr Therapeutics price target raised to $70 from $55 at Wells Fargo
- Crispr Therapeutics price target raised to $80 from $61 at Barclays
- Crispr Therapeutics price target raised to $112 from $110 at Chardan
